Wang Ling, Fang Xiaobin, Yang Yongling, Zhang Zhengping, Zhou Jianlin, Yang Jingsong, Liu Kaifeng, Wang Zhenhua
Department of Intensive Care Unit, the People's Hospital of Qiandongnan Miao and Dong Autonomous Prefecture, Kaili 556000, Guizhou, China. Corresponding author: Wang Ling, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018 Jan;30(1):24-28. doi: 10.3760/cma.j.issn.2095-4352.2018.01.005.
To design bundle treatment plan in the early stage for severe human infection by avian influenza H7N9, and explore its clinical efficacy and application value.
Fifteen patients with severe human infection by avian influenza H7N9 in Guizhou Province from December 29th, 2016 to June 7th, 2017 were enrolled. Patients admitted from March 6th, 2017 to June 7th, 2017 served as a prospective observation period (bundle treatment group), and those from December 29th, 2016 to March 5th, 2017 were selected as a historical control period (conventional treatment group). Conventional treatment group was given conventional treatment such as isolation, anti-virus, symptomatic treatment, and traditional Chinese medicine and so on. Bundle treatment group was given bundle treatment on the basis of conventional treatment, including isolation, anti-virus, respiratory support, restrictive fluid management, immunotherapy, inhibition of inflammation, antibiotic therapy, nutritional support, prevention of hospital acquired infection (HAP), individual sedation, continuous blood purification (CBP) for acute kidney injury (AKI) and severe acute respiratory distress syndrome (ARDS) patients, and intensive care. A cluster of bundle treatment team was set up to ensure that all measures carried out smoothly. The gender, age, onset to diagnosis time, acute physiology and chronic health evaluation II (APACHE II) score, oxygenation index (PaO/FiO) at admission, the length of intensive care unit (ICU) stay, total hospitalization time and prognosis of the two groups were observed. Correlation analysis between bundle therapy and prognosis was analyzed by Spearman correlation analysis. Receiver operating characteristic (ROC) curve was drawn, and the clinical value of bundle treatment was analyzed.
There was no significant difference in gender, age, onset to diagnosis time, APACHE II score, PaO/FiO, the length of ICU stay, or total hospitalization time between bundle treatment group (n = 9) and conventional treatment group (n = 6), but the death patients in the bundle treatment group was significantly fewer than those in conventional treatment group (cases: 2 vs. 5, χ = 3.225, P = 0.041). Correlation analysis showed that there was a significant correlation between the mortality and whether received bundle treatment or not in patients who infected by avian influenza H7N9 (r = -0.875, P = 0.018). ROC curve analysis showed that the area under the ROC curve (AUC) of non-bundle treatment for predicting the death in patients with severe human infection by avian influenza H7N9 was 0.938, 95% confidence interval (95%CI) was 0.795-1.000, the sensitivity was 88.88%, and the specificity was 98.62%.
Early bundle therapy has a significant effect on severe human infection by avian influenza H7N9, which can improve the prognosis and reduce the mortality of patients. It is worthy for clinical application.
设计人感染H7N9禽流感重症患者的早期集束化治疗方案,探讨其临床疗效及应用价值。
选取2016年12月29日至2017年6月7日贵州省15例人感染H7N9禽流感重症患者。将2017年3月6日至6月7日入院的患者作为前瞻性观察期(集束化治疗组),2016年12月29日至2017年3月5日入院的患者作为历史对照期(常规治疗组)。常规治疗组给予隔离、抗病毒、对症治疗、中药等常规治疗。集束化治疗组在常规治疗基础上给予集束化治疗,包括隔离、抗病毒、呼吸支持、限制性液体管理、免疫治疗、抑制炎症反应、抗生素治疗、营养支持、预防医院获得性感染(HAP)、个体化镇静、对急性肾损伤(AKI)及重症急性呼吸窘迫综合征(ARDS)患者行持续血液净化(CBP)及重症监护。组建集束化治疗团队,确保各项措施顺利实施。观察两组患者的性别、年龄、发病至诊断时间、急性生理与慢性健康状况评分系统II(APACHE II)评分、入院时氧合指数(PaO/FiO)、重症监护病房(ICU)住院时间、总住院时间及预后情况。采用Spearman相关分析对集束化治疗与预后的相关性进行分析。绘制受试者工作特征(ROC)曲线,分析集束化治疗的临床价值。
集束化治疗组(n = 9)与常规治疗组(n = 6)在性别、年龄、发病至诊断时间、APACHE II评分、PaO/FiO、ICU住院时间及总住院时间方面差异无统计学意义,但集束化治疗组死亡患者明显少于常规治疗组(例数:2例 vs. 5例,χ = 3.225,P = 0.041)。相关分析显示,H7N9禽流感感染患者的死亡率与是否接受集束化治疗有显著相关性(r = -0.875,P = 0.018)。ROC曲线分析显示,非集束化治疗预测人感染H7N9禽流感重症患者死亡的ROC曲线下面积(AUC)为0.938,95%可信区间(95%CI)为0.795 - 1.000,灵敏度为88.88%,特异度为98.62%。
早期集束化治疗对人感染H7N9禽流感重症患者有显著疗效,可改善患者预后,降低死亡率,值得临床推广应用。